AAF
NBIX icon

Andra AP-fonden’s Neurocrine Biosciences NBIX Stock Holding History

Andra AP-fonden’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.5M Buy
148,191
+80,291
+118% +$10.7M 0.23% 94
2025
Q4 		$9.63M Buy
+67,900
New +$9.84M 0.12% 220
2025
Q3 		– Sell
-27,400
Closed -$3.44M – 469
2025
Q2 		$3.44M Sell
27,400
-61,700
-69% -$7.08M 0.05% 306
2025
Q1 		$9.85M Sell
89,100
-11,200
-11% -$1.42M 0.16% 216
2024
Q4 		$13.7M Sell
100,300
-77,600
-44% -$9.6M 0.22% 179
2024
Q3 		$20.5M Buy
177,900
+16,600
+10% +$2.28M 0.3% 108
2024
Q2 		$22.2M Buy
161,300
+86,900
+117% +$11.9M 0.37% 85
2024
Q1 		$10.3M Buy
74,400
+1,600
+2% +$219K 0.18% 181
2023
Q4 		$9.59M Buy
72,800
+18,200
+33% +$2.09M 0.51% 67
2023
Q3 		$6.14M Sell
54,600
-13,300
-20% -$1.4M 0.36% 126
2023
Q2 		$6.4M Sell
67,900
-33,500
-33% -$3.27M 0.16% 294
2023
Q1 		$10.3M Buy
101,400
+8,700
+9% +$905K 0.27% 108
2022
Q4 		$11.1M Buy
92,700
+34,000
+58% +$3.98M 0.34% 38
2022
Q3 		$6.24M Buy
58,700
+11,800
+25% +$1.2M 0.2% 212
2022
Q2 		$4.57M Buy
+46,900
New +$4.33M 0.13% 357
2021
Q4 		$5.85M Buy
68,700
+17,200
+33% +$1.58M 0.12% 382
2021
Q3 		$4.94M Sell
51,500
-4,300
-8% -$406K 0.1% 427
2021
Q2 		$5.43M Buy
55,800
+44,700
+403% +$4.28M 0.11% 422
2021
Q1 		$1.08M Sell
11,100
-5,000
-31% -$524K 0.02% 562
2020
Q4 		$1.54M Buy
16,100
+8,500
+112% +$821K 0.03% 571
2020
Q3 		$731K Sell
7,600
-23,400
-75% -$2.71M 0.02% 604
2020
Q2 		$3.78M Buy
31,000
+4,300
+16% +$475K 0.11% 481
2020
Q1 		$2.31M Buy
26,700
+3,700
+16% +$362K 0.08% 569
2019
Q4 		$2.47M Buy
+23,000
New +$2.41M 0.07% 594

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Andra AP-fonden's NBIX Position: Q1 2026 in Review

Andra AP-fonden increased its Neurocrine Biosciences (NBIX) stake by 118% in Q1 2026, buying an estimated $10.7M and bringing the position to 148,191 shares worth $19.5M. The position accounts for 0.23% of the portfolio, ranked #94.

Andra AP-fonden first reported a position in NBIX in Q4 2019 and has held it in 24 quarters since. The position peaked at $22.2M in Q2 2024. 699 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Andra AP-fonden held 148,191 shares of Neurocrine Biosciences worth $19.5M as of Q1 2026.
  • Andra AP-fonden bought 80,291 Neurocrine Biosciences shares in Q1 2026, an estimated $10.7M.
  • Neurocrine Biosciences made up 0.23% of Andra AP-fonden's portfolio in Q1 2026, its #94 holding.
  • Andra AP-fonden first reported a position in Neurocrine Biosciences in Q4 2019 and has held it in 24 quarters since.
  • Andra AP-fonden's Neurocrine Biosciences position peaked at $22.2M in Q2 2024.
  • 699 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Andra AP-fonden's 13F filing for Q1 2026, filed 8 May 2026.